Abstract

Copyright: © 2014 Rahman MZ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Now-a-days the female’s breasts originate a major number of deaths for herself. The signatory of their motherhood is most commonly succumbed by malignancy. Breast cancer has accounted for 23% (1.38 million) of the total new cancer cases and 14% (458,400) of the total cancer deaths, placed it most frequent cancer and the leading cause of cancer death in female worldwide [1]. Breast cancer survival rate varies greatly throughout the world, ranging from 80% or above in North America, Sweden and Japan, to around 60% in middle-income countries and below 40% in low-income countries [2]. The projected 3 most common types of cancer in women in 2012 are breast, lung and colon-rectum, accounting for about the estimated cancer cases in women. Breast cancer alone is expected to account for 29% (226,870) of all new cancer cases among women [3]. Breast carcinoma is also the most common cancer in females of South Asia (India, Bangladesh, Nepal, Myanmar). In Bangladesh, the incidence of breast cancer is 26.3% in 2011 [4].

Highlights

  • Immunohistochemical stains of breast carcinoma biomarkers are currently performed on patient’s biopsy or surgical resections

  • We are being more dependent on IHC as well as progressing to molecular diagnosis for BRCA1/2 status

  • The Western world and the developed countries could adapt with these rapidly changing diagnostic modalities leading to an achievement of high survival rate of breast cancer patients reducing morbidity and mortality

Read more

Summary

Introduction

Immunohistochemical stains of breast carcinoma biomarkers are currently performed on patient’s biopsy or surgical resections. We are being more dependent on IHC as well as progressing to molecular diagnosis for BRCA1/2 status. The Western world and the developed countries could adapt with these rapidly changing diagnostic modalities leading to an achievement of high survival rate of breast cancer patients reducing morbidity and mortality.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call